Search results
Ono Pharmaceutical acquires cancer-focused biopharma Deciphera for $2.4bn
Pharmaceutical Technology via Yahoo Finance· 4 days agoThe deal has been unanimously approved by both companies’ boards of directors and is expected to...
Why Is Cancer Focused Deciphera Pharmaceuticals Stock Skyrocketing On Monday?
Benzinga via Yahoo Finance· 4 days agoOn Monday, Japanese pharma company ONO Pharmaceutical agreed to acquire Deciphera Pharmaceuticals...
‘Is this real?’ Greely baseball player surprised his play airs on ‘SportsCenter’
Portland Press Herald· 1 day agoWhen he was making the play from third base, Marky Axelsen said he didn’t think it was all that...
Greenberg Traurig Represents ONO Pharmaceutical Co. in $2.4B Acquisition of Deciphera...
PRWeb· 3 days agoGlobal law firm Greenberg Traurig, LLP represented Japan-based global specialty pharmaceutical company ONO Pharmaceutical Co. in its acquisition of Waltham, Massachusetts ...
Revvity: Q1 Earnings Snapshot
Associated Press Finance via Yahoo Finance· 4 days agoWALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Revvity, Inc. (RVTY) on Monday reported first-quarter profit of $26 million. The Waltham, Massachusetts-based ...
Deciphera acquisition by ONO Pharmaceutical at $2.4 billion By Investing.com
Investing.com· 2 days agoDeciphera Pharmaceuticals , Inc. (NASDAQ: NASDAQ:DCPH), a biopharmaceutical company specializing in...
Repligen: Q1 Earnings Snapshot
Associated Press Finance via Yahoo Finance· 2 days agoWALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Repligen Corp. (RGEN) on Wednesday reported first-quarter net income of $2.1 million. The Waltham, Massachusetts
ONO to buy Deciphera Pharmaceuticals at a huge premium | Invezz
Invezz· 4 days agoDeciphera Pharmaceuticals Inc (NASDAQ: DCPH) is up a whopping 75% today after ONO Pharmaceutical...
Why Is Cancer Focused Deciphera Pharmaceuticals Stock Skyrocketing On Monday? - Deciphera...
Benzinga· 4 days agoOn Monday, Japanese pharma company ONO Pharmaceutical agreed to acquire Deciphera Pharmaceuticals...
Apellis Pharmaceuticals stock has lost 40% in 2024: buy the dip? | Invezz
Invezz· 3 days agoApellis Pharmaceuticals Inc (NASDAQ: APLS) is down nearly 40% versus its year-to-date high but a Mizuho analyst does not see it as an opportunity to buy per se. Graig Suvannavejh reiterated ...
